Menu

Impact Events

More
Date Lead Company Event Type Approval Change Approval Likelihood
5/25/23 Artiva Biotherapeutics AB-101 (Artiva) for Non-Hodgkin's Lymphoma (NHL) Subscribers Only Subscribers Only Subscribers Only
5/25/23 Merck (MRK) Reblozyl for Myelodysplastic Syndrome (MDS) Subscribers Only Subscribers Only Subscribers Only
5/25/23 AstraZeneca (AZN) Imjudo for Hepatocellular (Liver) Cancer (HCC) (Including Secondary Metastases) Subscribers Only Subscribers Only Subscribers Only
5/25/23 Roche (RHHBY) Tecentriq for Colorectal Cancer (CRC) Subscribers Only Subscribers Only Subscribers Only
5/25/23 Bristol Myers Squibb (BMY) Breyanzi for Chronic Lymphocytic Leukemia (CLL)/Small Cell Lymphocytic Lymphoma (SLL) - NHL Subscribers Only Subscribers Only Subscribers Only

Upcoming Catalysts

More
Expected Date Range Lead Company Drug Expected Catalyst
05/26/23 Subscribers Only Subscribers Only Regulatory - PDUFA/Approval Decision (U.S.)
05/27/23 Subscribers Only Subscribers Only Trial Data - Top-Line Results
05/27/23 Subscribers Only Subscribers Only Trial Data - Final Results
Now - 05/30/23 Subscribers Only Subscribers Only Trial Announcement - Initiation
Now - 05/30/23 Subscribers Only Subscribers Only Regulatory - Approval Decision (Japan)
Back to the top Back to the top